IN-DATE
GWC-12325LG-FT-SD: CSI ViperWire Advance Guidewire 0.012" x 325cm
Sign in to add this product to your favorites!
| Price: | $139.99 EACH |
|---|---|
| Quantity: | |
| In Stock: | 3 eaches |
| Expiration: | 08-2026 |
Additional Details
Abbott CSI ViperWire Advance Coronary Guide Wire
To be used exclusively with CSI Diamondback 360 Coronary Orbital Atherectomy System
AccessGUDID Info
- FDA Product Code: MCX
- FDA Product Code Name: Catheter, Coronary, Atherectomy
- GMDN Term Code: 35094
- GMDN Term Name: Cardiac/peripheral vascular guidewire, single-use
- GMDN Term Description: A long, thin, sterile wire intended to be percutaneously placed into the cardiac vasculature (ventricles or coronary vessels) to function as a guide for the introduction, positioning, and/or operation of a device (e.g., catheter, pacing lead); it may also be used in the peripheral vasculature. It may be made of metal (e.g., stainless steel, Nitinol), or polymer and/or glass materials to provide MRI-compatibility, with or without coating, and is available in a variety of distal tip designs. It is used for various diagnostic and interventional procedures, and may include devices used to facilitate manipulation (e.g., torque device). This is a single-use device.
Manufacturer
Cardiovascular Systems, Inc. (CSI), now a part of Abbott, specialized in innovative solutions for the treatment of peripheral and coronary artery disease through its proprietary orbital atherectomy systems. CSI’s flagship technologies include the Diamondback 360® Peripheral Orbital Atherectomy System and the Diamondback 360® Coronary Orbital Atherectomy System, both designed to modify calcified plaque and improve vessel compliance prior to stent placement or balloon angioplasty.
These systems use a diamond-coated crown that orbits within the vessel, sanding away plaque while preserving healthy tissue and facilitating better device delivery. CSI’s focus on challenging arterial disease—particularly in heavily calcified lesions—made it a valuable addition to Abbott’s vascular portfolio following its acquisition in 2023, further expanding minimally invasive treatment options for complex cardiovascular cases.
